Gonadotropin signalling in epithelial ovarian cancer

Cancer Letters

Volumn 324, Issue 2, 2012, Pages 152-159

  Mertens Walker, Inga ^a,b   Baxter, Robert C ^a   Marsh, Deborah J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

FSH; Gonadotropins; LH; Ovarian cancer; Signalling pathways

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; FOLLITROPIN; FOLLITROPIN RECEPTOR; GONADORELIN; GONADORELIN RECEPTOR; GONADOTROPIN; GONADOTROPIN RECEPTOR; INTERLEUKIN 6; LUTEINIZING HORMONE; LUTEINIZING HORMONE RECEPTOR; MESSENGER RNA; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C;

APOPTOSIS; CANCER CELL; CARCINOGENESIS; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; DISEASE ASSOCIATION; EPITHELIUM CELL; GENE; GENE EXPRESSION REGULATION; HORMONAL REGULATION; HORMONE ACTION; HUMAN; IN VIVO STUDY; INTERLEUKIN 6 GENE; NONHUMAN; ONCOGENE; OVARY CANCER; OVARY CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR MODEL; TUMOR VASCULARIZATION;

EID: 84864378300     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.05.017     Document Type: Review

References (131)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2012, 62:10-29.
3. Kurman R.J., Visvanathan K., Roden R., Wu T.C., Shih Ie M. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am. J. Obstet. Gynecol. 2008, 198:351-356.
4. Auersperg N., Wong A.S., Choi K.C., Kang S.K., Leung P.C. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev. 2001, 22:255-288.
5. Auersperg N. The origin of ovarian carcinomas: a unifying hypothesis. Int. J. Gynecol. Pathol. 2011, 30:12-21.
6. Li J., Abushahin N., Pang S., Xiang L., Chambers S.K., Fadare O., Kong B., Zheng W. Tubal origin of 'ovarian' low-grade serous carcinoma. Mod. Pathol. 2011, 24:1488-1499.
7. Munksgaard P.S., Blaakaer J. The association between endometriosis and gynecological cancers and breast cancer: a review of epidemiological data. Gynecol. Oncol. 2011, 123:157-163.
8. Gram I.T., Lukanova A., Brill I., Braaten T., Lund E., Lundin E., Overvad K., Tjonneland A., Clavel-Chapelon F., Chabbert-Buffet N., Bamia C., Trichopoulou A., Zylis D., Masala G., Berrino F., Galasso R., Tumino R., Sacerdote C., Gavrilyuk O., Kristiansen S., Rodriguez L., Bonet C., Huerta J.M., Barricarte A., Sanchez M.J., Dorronsoro M., Jirstrom K., Almquist M., Idahl A., Bueno-de-Mesquita H.B., Braem M., Onland-Moret C., Tsilidis K.K., Allen N.E., Fedirko V., Riboli E., Kaaks R. Cigarette smoking and risk of histological subtypes of epithelial ovarian cancer in the EPIC cohort study. Int. J. Cancer 2011, 8:90.
9. Vaughan S., Coward J.I., Bast R.C., Berchuck A., Berek J.S., Brenton J.D., Coukos G., Crum C.C., Drapkin R., Etemadmoghadam D., Friedlander M., Gabra H., Kaye S.B., Lord C.J., Lengyel E., Levine D.A., McNeish I.A., Menon U., Mills G.B., Nephew K.P., Oza A.M., Sood A.K., Stronach E.A., Walczak H., Bowtell D.D., Balkwill F.R. Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer 2011, 11:719-725.
10. Stadel B.V. Letter: the etiology and prevention of ovarian cancer. Am. J. Obstet. Gynecol. 1975, 123:772-774.
11. N. Howlader, A.M. Noone, M. Krapcho, N. Neyman, R. Aminou, W. Waldron, S.F. Altekruse, C.L. Kosary, J. Ruhl, Z. Tatalovich, H. Cho, A. Mariotto, M.P. Eisner, D.R. Lewis, H.S. Chen, E.J. Feuer, K.A. Cronin, B.K. Edwards, Cancer of the Ovary. SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, based on November 2010 SEER data submission, 2011. http://seer.cancer.gov/csr/1975_2008/.
12. Chakravarti S., Collins W.P., Forecast J.D., Newton J.R., Oram D.H., Studd J.W. Hormonal profiles after the menopause. Br. Med. J. 1976, 2:784-787.
13. Choi J.H., Wong A.S., Huang H.F., Leung P.C. Gonadotropins and ovarian cancer. Endocr. Rev. 2007, 28:440-461.
14. Nichols H.B., Trentham-Dietz A., Hampton J.M., Titus-Ernstoff L., Egan K.M., Willett W.C., Newcomb P.A. From menarche to menopause: trends among US women born from 1912 to 1969. Am. J. Epidemiol. 2006, 164:1003-1011.
15. Horner M.J., Ries L.A.G., Krapcho M., Neyman N., Aminou R., Howlader N., Altekruse S.F., Feuer E.J., Huang L., Mariotto A., Miller B.A., L e wis D.R., Eisner M.P., Stinchcomb D.G., Edwards B.K. SEER Cancer Statistics Review, 1975-2006. J. Natl. Cancer I. 2009, 9.
16. Halperin R., Hadas E., Langer R., Bukovsky I., Schneider D. Peritoneal fluid gonadotropins and ovarian hormones in patients with ovarian cancer. Int. J. Gynecol. Cancer 1999, 9:502-507.
17. Rzepka-Gorska I., Chudecka-Glaz A., Kosmowska B. FSH and LH serum/tumor fluid ratios and malignant tumors of the ovary. Endocr.-Relat. Cancer 2004, 11:315-321.
18. Halperin R., Pansky M., Vaknin Z., Zehavi S., Bukovsky I., Schneider D. Luteinizing hormone in peritoneal and ovarian cyst fluids: a predictor of ovarian carcinoma. Eur. J. Obstet. Gynecol. Reprod. Biol. 2003, 110:207-210. T.A.U.I. Sackler Faculty of Medicine.
19. Chen F.C., Oskay-Ozcelik G., Buhling K.J., Kopstein U., Mentze M., Lichtenegger W., Sehouli J. Prognostic value of serum and ascites levels of estradiol, FSH, LH and prolactin in ovarian cancer. Anticancer Res. 2009, 29:1575-1578.
20. Chudecka-Glaz A., Rzepka-Gorska I. Concentrations of follicle stimulating hormone are increased in ovarian tumor fluid: implications for the management of ovarian cancer. Eur. J. Obstet. Gynecol. Reprod. Biol. 2008, 29:37-42.
21. Helzlsouer K.J., Alberg A.J., Gordon G.B., Longcope C., Bush T.L., Hoffman S.C., Comstock G.W. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 1995, 274:1926-1930.
22. McSorley M.A., Alberg A.J., Allen D.S., Allen N.E., Brinton L.A., Dorgan J.F., Kaaks R., Rinaldi S., Helzlsouer K.J. Prediagnostic circulating follicle stimulating hormone concentrations and ovarian cancer risk. Int. J. Cancer 2009, 125:674-679.
23. Arslan A.A., Zeleniuch-Jacquotte A., Lundin E., Micheli A., Lukanova A., Afanasyeva Y., Lenner P., Krogh V., Muti P., Rinaldi S., Kaaks R., Berrino F., Hallmans G., Toniolo P. Serum follicle-stimulating hormone and risk of epithelial ovarian cancer in postmenopausal women. Cancer Epidemiol. Biomarkers Prev. 2003, 12:1531-1535.
24. Riman T., Persson I., Nilsson S. Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Clin. Endocrinol. 1998, 49:695-707.
25. Schildkraut J.M., Schwingl P.J., Bastos E., Evanoff A., Hughes C. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet. Gynecol. 1996, 88:554-559.
26. Bosch E., Ezcurra D. Individualised controlled ovarian stimulation (iCOS): maximising success rates for assisted reproductive technology patients. Reprod. Biol. Endocrinol. 2011, 9:82.
27. Whittemore A.S., Harris R., Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am. J. Epidemiol. 1992, 136:1212-1220.
28. Sanner K., Conner P., Bergfeldt K., Dickman P., Sundfeldt K., Bergh T., Hagenfeldt K., Janson P.O., Nilsson S., Persson I. Ovarian epithelial neoplasia after hormonal infertility treatment: long-term follow-up of a historical cohort in Sweden. Fertil. Steril. 2009, 91:1152-1158.
29. Jensen A., Sharif H., Frederiksen K., Kjaer S.K. Use of fertility drugs and risk of ovarian cancer: Danish Population Based Cohort Study. Br. Med. J. 2009, 338:b249.
30. Ness R.B., Cramer D.W., Goodman M.T., Kjaer S.K., Mallin K., Mosgaard B.J., Purdie D.M., Risch H.A., Vergona R., Wu A.H. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am. J. Epidemiol. 2002, 155:217-224.
31. Doyle P., Maconochie N., Beral V., Swerdlow A.J., Tan S.L. Cancer incidence following treatment for infertility at a clinic in the UK. Hum. Reprod. 2002, 17:2209-2213.
32. Brinton L.A., Lamb E.J., Moghissi K.S., Scoccia B., Althuis M.D., Mabie J.E., Westhoff C.L. Ovarian cancer risk after the use of ovulation-stimulating drugs. Obstet. Gynecol. 2004, 103:1194-1203.
33. Matei M.C., Caruntu I.D., Negura L., Petrariu F.D., Ifrim S., Acatrinei L., Sulugiuc A., Azoicai D. The assessment of relations between main histologic type of ovarian cancer and some risk and prognostic factors. Rev. Med. Chir. Soc. Med. Nat. Iasi. 2010, 114:1135-1141.
34. Beral V., Bull D., Green J., Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007, 369:1703-1710.
35. Syed V., Ulinski G., Mok S.C., Yiu G.K., Ho S.M. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res. 2001, 61:6768-6776.
36. Y. Wang, J. Dean, T. Badgery-Parker, E. Sullivan, Assisted reproduction technology in Australia and New Zealand 2006. Assisted reproduction technology series no. 12. AIHW cat. no. PER 43. Sydney: AIHW National Perinatal Statistics Unit, 2008.
37. Chambers G.M., Sullivan E.A., Ishihara O., Chapman M.G., Adamson G.D. The economic impact of assisted reproductive technology: a review of selected developed countries. Fertil. Steril. 2009, 91:2281-2294.
38. Ascoli M., Fanelli F., Segaloff D.L. The lutropin/choriogonadotropin receptor, a 2002 perspective. Endocr. Rev. 2002, 23:141-174.
39. Bukovsky A., Indrapichate K., Fujiwara H., Cekanova M., Ayala M., Dominguez R., Caudle M., Wimalsena J., Elder R., Copas P., Foster J., Fernando R., Henley D., Upadhyaya N. Multiple luteinizing hormone receptor (LHR) protein variants, interspecies reactivity of anti-LHR mAb clone 3B5, subcellular localization of LHR in human placenta, pelvic floor and brain, and possible role for LHR in the development of abnormal pregnancy, pelvic floor disorders and Alzheimer's disease. Reprod. Biol. Endocrinol. 2003, 1:46.
40. Mandai M., Konishi I., Kuroda H., Fukumoto M., Komatsu T., Yamamoto S., Nanbu K., Rao C.V., Mori T. Messenger ribonucleic acid expression of LH/hCG receptor gene in human ovarian carcinomas. Eur. J. Cancer 1997, 33:1501-1507.
41. Parrott J.A., Doraiswamy V., Kim G., Mosher R., Skinner M.K. Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer. Mol. Cell. Endocrin. 2001, 172:213-222.
42. Zheng W., Magid M.S., Kramer E.E., Chen Y.T. Follicle-stimulating hormone receptor is expressed in human ovarian surface epithelium and fallopian tube. Am. J. Pathol. 1996, 148:47-53.
43. Radu A., Pichon C., Camparo P., Antoine M., Allory Y., Couvelard A., Fromont G., Hai M.T.V., Ghinea N. Expression of follicle-stimulating hormone receptor in tumor blood vessels. New Eng. J. Med. 2010, 363:1621-1630.
44. Lu J.J., Zheng Y., Kang X., Yuan J.-M., Lauchlan S.C., Pike M.C., Zheng W. Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer. Gynecol. Oncol. 2000, 79:158-168.
45. Wang J., Lin L., Parkash V., Schwartz P.E., Lauchlan S.C., Zheng W. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems. Int. J. Cancer 2003, 103:328-334.
46. LaPolt P.S., Jia X.-C., Sincich C., Hsueh A.J.W. Ligand-lnduced down-regulation of testicular and ovarian luteinizing hormone (LH) receptors is preceded by tissue-specific inhibition of alternatively processed LH receptor transcripts. Mol. Endocrinol. 1991, 5:397-403.
47. LaPolt P.S., Oikawa M., Jia X.-C., Dargan C., Hsueh A.J.W. Gonadotropin-induced up-and downregulation of rat ovarian LH receptor message levels during follicular growth, ovulation and luteinization. Endocrinology 1990, 126:3277-3279.
48. Themmen A.P., Blok L.J., Post M., Baarends W.M., Hoogerbrugge J.W., Parmentier M., Vassart G., Grootegoed J.A. Follitropin receptor down-regulation involves a cAMP-dependent post-transcriptional decrease of receptor mRNA expression. Mol. Cell. Endocrinol. 1991, 78:R7-13.
49. Lenhard M., Lennerova T., Ditsch N., Kahlert S., Friese K., Mayr D., Jeschke U. Opposed roles of follicle-stimulating hormone and luteinizing hormone receptors in ovarian cancer survival. Histopathology 2011, 58:990-994.
50. Zhang Z., Jia L., Feng Y., Zheng W. Overexpression of follicle-stimulating hormone receptor facilitates the development of ovarian epithelial cancer. Cancer Lett. 2009, 278:56-64.
51. Choi J.H., Choi K.C., Auersperg N., Leung P.C. Overexpression of follicle-stimulating hormone receptor activates oncogenic pathways in preneoplastic ovarian surface epithelial cells. J. Clin. Endocrinol. Metab. 2004, 89:5508-5516.
52. Warrenfeltz S.W., Lott S.A., Palmer T.M., Gray J.C., Puett D. Luteinizing hormone-induced up-regulation of ErbB-2 Is insufficient stimulant of growth and invasion in ovarian cancer cells. Mol. Cancer Res. 2008, 6:1775-1785.
53. LeMaire W.J. Mechanism of mammalian ovulation. Steroids 1989, 54:455-469.
54. Stocco D.M., Wang X., Jo Y., Manna P.R. Multiple signaling pathways regulating steroidogenesis and steroidogenic acute regulatory protein expression: more complicated than we thought. Mol. Endocrinol. 2005, 19:2647-2659.
55. Slot K.A., de Boer-Brouwer M., Houweling M., Vaandrager A.B., Dorrington J.H., Teerds K.J. Luteinizing hormone inhibits Fas-induced apoptosis in ovarian surface epithelial cell lines. J. Endocrinol. 2006, 188:227-239.
56. Pon Y.L., Auersperg N., Wong A.S. Gonadotropins regulate N-cadherin-mediated human ovarian surface epithelial cell survival at both post-translational and transcriptional levels through a cyclic AMP/protein kinase A pathway. J. Biol. Chem. 2005, 280:15438-15448.
57. Choi J.H., Chen C.L., Poon S.L., Wang H.S., Leung P.C. Gonadotropin-stimulated EGFR expression in human ovarian surface epithelial cells: involvement of cyclic AMP-dependent Epac pathway. Endocr.-Relat. Cancer 2008, 7.
58. Parker P.J., Murray-Rust J. PKC at a glance. J. Cell Sci. 2004, 117:131-132.
59. Rosse C., Linch M., Kermorgant S., Cameron A.J.M., Boeckeler K., Parker P.J. PKC and the control of localized signal dynamics. Nat. Rev. Mol. Cell. Biol. 2010, 11:103-112.
60. 2+ mobilization. Studies with the cloned murine luteinizing hormone receptor expressed in L cells. J. Biol. Chem. 1992, 267:4479-4488.
61. Herrlich A., Kuhn B., Grosse R., Schmid A., Schultz G., Gudermann T. Involvement of Gs and Gi proteins in dual coupling of the luteinizing hormone receptor to adenylyl cyclase and phospholipase C. J. Biol. Chem. 1996, 271:16764-16772.
62. Minegishi T., Tano M., Shinozaki H., Nakamura K., Abe Y., Ibuki Y., Miyamoto K. Dual coupling and down regulation of human FSH receptor in CHO cells. Life Sci. 1997, 60:2043-2050.
63. Ohtani K., Sakamoto H., Kikuchi A., Nakayama Y., Idei T., Igarashi N., Matukawa T., Satoh K. Follicle-stimulating hormone promotes the growth of human epithelial ovarian cancer cells through the protein kinase C-mediated system. Cancer Lett. 2001, 166:207-213.
64. Mertens-Walker I., Bolitho C., Baxter R.C., Marsh D.J. Gonadotropin-induced ovarian cancer cell migration and proliferation require extracellular signal-regulated kinase 1/2 activation regulated by calcium and protein kinase C{delta}. Endocr.-Relat. Cancer 2010, 17:335-349.
65. Choi K.C., Auersperg N., Leung P.C. Mitogen-activated protein kinases in normal and (pre)neoplastic ovarian surface epithelium. Reprod. Biol. Endocrinol. 2003, 1:71.
66. Woodgett J.R., Avruch J., Kyriakis J. The stress activated protein kinase pathway. Cancer Surveys 1996, 27:127-138.
67. Yoon S., Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 2006, 24:21-44.
68. Grant S., Qiao L., Dent P. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front. Biosci. 2002, 7:376-389.
69. van Biesen T., Luttrell L.M., Hawes B.E., Lefkowitz R.J. Mitogenic signaling via G protein-coupled receptors. Endocr. Rev. 1996, 17:698-714.
70. Choi K.C., Kang S.K., Tai C.J., Auersperg N., Leung P.C. Follicle-stimulating hormone activates mitogen-activated protein kinase in preneoplastic and neoplastic ovarian surface epithelial cells. J. Clin. Endocrinol. Metab. 2002, 87:2245-2253.
71. Zhang Z., Liao H., Chen X., Zheng Y., Liu Y., Tao X., Gu C., Dong L., Duan T., Yang Y., Liu X., Yu Y., Feng Y. Luteinizing hormone upregulates survivin and inhibits apoptosis in ovarian epithelial tumors. Eur. J. Obstet. Gynecol. Reprod. Biol. 2011, 155:69-74.
72. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase-AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2:489-501.
73. Shayesteh L., Lu Y., Kuo W.L., Baldocchi R., Godfrey T., Collins C., Pinkel D., Powell B., Mills G.B., Gray J.W. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. 1999, 21:99-102.
74. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
75. Keniry M., Parsons R. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008, 27:5477-5485.
76. Swiersz L.M. Role of endometriosis in cancer and tumor development. Ann. N. Y. Acad. Sci. 2002, 955:281-292. (discussion 293-285, 396-406).
77. Altomare D.A., Wang H.Q., Skele K.L., Rienzo A.D., Klein-Szanto A.J., Godwin A.K., Testa J.R. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004, 23:5853-5857.
78. Cheng J.Q., Lindsley C.W., Cheng G.Z., Yang H., Nicosia S.V. The Akt//PKB pathway: molecular target for cancer drug discovery. Oncogene 2005, 24:7482-7492.
79. Choi J.H., Choi K.C., Auersperg N., Leung P.C. Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells. Cancer Res. 2006, 66:3912-3920.
80. Huang Y., Hua K., Zhou X., Jin H., Chen X., Lu X., Yu Y., Zha X., Feng Y. Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. Cell Res. 2008, 18:780-791.
81. Huang Y., Jin H., Liu Y., Zhou J., Ding J., Cheng K.W., Yu Y., Feng Y. FSH inhibits ovarian cancer cell apoptosis by up-regulating survivin and down-regulating PDCD6 and DR5. Endocr.-Relat. Cancer 2011, 18:13-26.
82. Liao H., Zhou Q., Gu Y., Duan T., Feng Y. Luteinizing hormone facilitates angiogenesis in ovarian epithelial tumor cells and metformin inhibits the effect through the mTOR signaling pathway. Oncol. Rep. 2012, 27:1873-1878.
83. Radosh L. Drug treatments for polycystic ovary syndrome. Am. Fam. Physician 2009, 79:671-676.
84. Liao H., Zhou Q., Zhang Z., Wang Q., Sun Y., Yi X., Feng Y. NRF2 is overexpressed in ovarian epithelial carcinoma and is regulated by gonadotrophin and sex-steroid hormones. Oncol. Rep. 2012, 27:1918-1924.
85. Wimalasena J., Dostal R., Meehan D. Gonadotropins, estradiol, and growth factors regulate epithelial ovarian cancer cell growth. Gynecol. Oncol. 1992, 46:345-350.
86. Park Y.H., Kim S.J., Jeong B.H., Herzog T.J., Wright J., Kitajewski J., Rhim C.C., Jang P.R., Kang J.B. Follicular stimulating hormone enhances Notch 1 expression in SK-OV-3 ovarian cancer cells. J. Gynecol. Oncol. 2010, 21:119-124.
87. Ivarsson K., Sundfeldt K., Brannstrom M., Hellberg P., Janson P.O. Diverse effects of FSH and LH on proliferation of human ovarian surface epithelial cells. Hum. Reprod. 2001, 16:18-23.
88. Zheng W., Lu J.J., Luo F., Zheng Y., Feng Y., Felix J.C., Lauchlan S.C., Pike M.C. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol. Oncol. 2000, 76:80-88.
89. Choi J.H., Choi K.C., Auersperg N., Leung P.C. Gonadotropins upregulate the epidermal growth factor receptor through activation of mitogen-activated protein kinases and phosphatidyl-inositol-3-kinase in human ovarian surface epithelial cells. Endocr.-Relat. Cancer 2005, 12:407-421.
90. Tourgeman D.E., Lu J.J., Boostanfar R., Amezcua C., Felix J.C., Paulson R.J. Human chorionic gonadotropin suppresses ovarian epithelial neoplastic cell proliferation in vitro. Fertil. Steril. 2002, 78:1096-1099.
91. Pani G., Galeotti T., Chiarugi P. Metastasis: cancer cell's escape from oxidative stress. Cancer Metast. Rev. 2010, 29:351-378.
92. Yilmaz M., Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metast. Rev. 2009, 28:15-33.
93. Kenny H.A., Krausz T., Yamada S.D., Lengyel E. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int. J. Cancer 2007, 121:1463-1472.
94. Pickel H., Lahousen M., Stettner H., Girardi F. The spread of ovarian cancer. Baillière's Clin. Obstet. Gynaecol. 1989, 3:3-12.
95. Schiffenbauer Y.S., Meir G., Maoz M., Even-Ram S.C., Bar-Shavit R., Neeman M. Gonadotropin stimulation of MLS human epithelial ovarian carcinoma cells augments cell adhesion mediated by CD44 and by alpha(v)-integrin. Gynecol. Oncol. 2002, 84:296-302.
96. Hironori T., Hidetaka K., Monjura B., Xiaoguang L., Makoto N., Hideyuki O., Hitoshi O. Roles of luteinizing hormone/chorionic gonadotropin receptor in anchorage-dependent and -independent growth in human ovarian surface epithelial cell lines. Cancer Sci. 2003, 94:953-959.
97. Tzuman Y.C., Sapoznik S., Granot D., Nevo N., Neeman M. Peritoneal adhesion and angiogenesis in ovarian carcinoma are inversely regulated by hyaluronan: the role of gonadotropins. Neoplasia 2010, 12:51-60.
98. Kenny H.A., Kaur S., Coussens L.M., Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J. Clin. Invest. 2008, 118:1367-1379.
99. Lau M.T., Wong A.S., Leung P.C. Gonadotropins induce tumor cell migration and invasion by increasing cyclooxygenases expression and prostaglandin E(2) production in human ovarian cancer cells. Endocrinology 2010, 151:2985-2993.
100. Schiffenbauer Y.S., Abramovitch R., Meir G., Nevo N., Holzinger M., Itin A., Keshet E., Neeman M. Loss of ovarian function promotes angiogenesis in human ovarian carcinoma. PNAS 1997, 94:13203-13208.
101. Sapoznik S., Cohen B., Tzuman Y., Meir G., Ben-Dor S., Harmelin A., Neeman M. Gonadotropin-regulated lymphangiogenesis in ovarian cancer is mediated by LEDGF-induced expression of VEGF-C. Cancer Res. 2009, 69:9306-9314.
102. Wang J., Luo F., Lu J.J., Chen P.K., Liu P., Zheng W. VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors. Int. J. Cancer 2002, 97:163-167.
103. Nash M.A., Ferrandina G., Gordinier M., Loercher A., Freedman R.S. The role of cytokines in both the normal and malignant ovary. Endocr.-Relat. Cancer 1999, 6:93-107.
104. Watson J.M., Sensintaffar J.L., Berek J.S., Martinez-Maza O. Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res. 1990, 50:6959-6965.
105. Nilsson M.B., Langley R.R., Fidler I.J. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res. 2005, 65:10794-10800.
106. Kulbe H., Chakravarty P., Leinster D.A., Charles K.A., Kwong J., Thompson R.G., Coward J.I., Schioppa T., Robinson S.C., Gallagher W.M., Galletta L., Salako M.A., Smyth J.F., Hagemann T., Brennan D.J., Bowtell D.D., Balkwill F.R. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res. 2012, 72:66-75.
107. Lo C.W., Chen M.W., Hsiao M., Wang S., Chen C.A., Hsiao S.M., Chang J.S., Lai T.C., Rose-John S., Kuo M.L., Wei L.H. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res. 2011, 71:424-434.
108. Syed V., Ulinski G., Mok S.C., Ho S.M. Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells. J. Natl. Cancer 2002, I(94):617-629.
109. Li B.Y., Mohanraj D., Olson M.C., Moradi M., Twiggs L., Carson L.F., Ramakrishnan S. Human ovarian epithelial cancer cells cultures in vitro express both interleukin 1 alpha and beta genes. Cancer Res. 1992, 52:2248-2252.
110. Ivarsson K., Ekerydh A., Fyhr I.M., Janson P.O., Brannstrom M. Upregulation of interleukin-8 and polarized epithelial expression of interleukin-8 receptor A in ovarian carcinomas. Acta Obstet. Gynecol. Scand. 2000, 79:777-784.
111. Moscova M., Marsh D.J., Baxter R.C. Protein chip discovery of secreted proteins regulated by the phosphatidylinositol 3-kinase pathway in ovarian cancer cell lines. Cancer Res. 2006, 66:1376-1383.
112. Bolitho C., Hahn M.A., Baxter R.C., Marsh D.J. The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor. Endocr.-Relat. Cancer 2010, 17:929-940.
113. Jia L., Yi X.F., Zhang Z.B., Zhuang Z.P., Li J., Chambers S.K., Kong B.H., Zheng W. Prohibitin as a novel target protein of luteinizing hormone in ovarian epithelial carcinogenesis. Neoplasma 2011, 58:104-109.
114. Ho S.M., Lau K.M., Mok S.C., Syed V. Profiling follicle stimulating hormone-induced gene expression changes in normal and malignant human ovarian surface epithelial cells. Oncogene 2003, 22:4243-4256.
115. Ji Q., Liu P.I., Chen P.K., Aoyama C. Follicle stimulating hormone-induced growth promotion and gene expression profiles on ovarian surface epithelial cells. Int. J. Cancer 2004, 112:803-814.
116. Cui J., Miner B.M., Eldredge J.B., Warrenfeltz S.W., Dam P., Xu Y., Puett D. Regulation of gene expression in ovarian cancer cells by luteinizing hormone receptor expression and activation. BMC Cancer 2011, 11:280.
117. Dahiya N., Morin P.J. MicroRNAs in ovarian carcinomas. Endocr.-Relat. Cancer 2010, 17:F77-89.
118. Yao N., Lu C.L., Zhao J.J., Xia H.F., Sun D.G., Shi X.Q., Wang C., Li D., Cui Y., Ma X. A network of miRNAs expressed in the ovary are regulated by FSH. Front. Biosci. 2009, 14:3239-3245.
119. Pan X., Wang Z.X., Wang R. MicroRNA-21: a novel therapeutic target in human cancer. Cancer. Biol. Ther. 2011, 10:1224-1232.
120. Lou Y., Yang X., Wang F., Cui Z., Huang Y. MicroRNA-21 promotes the cell proliferation, invasion and migration abilities in ovarian epithelial carcinomas through inhibiting the expression of PTEN protein. Int. J. Mol. Med. 2010, 26:819-827.
121. Cui J., Eldredge J.B., Xu Y., Puett D. MicroRNA expression and regulation in human ovarian carcinoma cells by luteinizing hormone. PLoS ONE 2011, 6:e21730.
122. Garson K., Shaw T.J., Clark K.V., Yao D.-S., Vanderhyden B.C. Models of ovarian cancer - are we there yet?. Mol. Cell. Endocrinol. 2005, 239:15-26.
123. Vanderhyden B., Shaw T., Ethier J.-F. Animal models of ovarian cancer. Reprod. Biol. Endocrinol. 2003, 1:67.
124. Connolly D.C., Bao R., Nikitin A.Y., Stephens K.C., Poole T.W., Hua X., Harris S.S., Vanderhyden B.C., Hamilton T.C. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res. 2003, 63:1389-1397.
125. McGowan L., Davis R.H. Intrasplenic ovarian grafts in Syrian hamsters and peritoneal fluid cellular distribution. Proc. Soc. Exp. Biol. Med. 1970, 134:507-509.
126. Stewart S.L., Querec T.D., Ochman A.R., Gruver B.N., Bao R., Babb J.S., Wong T.S., Koutroukides T., Pinnola A.D., Klein-Szanto A., Hamilton T.C., Patriotis C. Characterization of a carcinogenesis rat model of ovarian preneoplasia and neoplasia. Cancer Res. 2004, 64:8177-8183.
127. Beck E.P., Vincenti D., Licht P., Berkholz A., Jager W., Lang N., Merkle E. In vitro activity of human chorionic gonadotropin (hCG)-doxorubicin conjugates against ovarian cancer cells. Anticancer Res. 2000, 20:3001-3006.
128. Gebauer G., Mueller N., Fehm T., Berkholz A., Beck E.P., Jaeger W., Licht P. Expression and regulation of luteinizing hormone/human chorionic gonadotropin receptors in ovarian cancer and its correlation to human chorionic gonadotropin-doxorubicin sensitivity. Am. J. Obstet. Gynecol. 2004, 190:1621-1628. (discussion 1628).
129. Zhang X.Y., Chen J., Zheng Y.F., Gao X.L., Kang Y., Liu J.C., Cheng M.J., Sun H., Xu C.J. Follicle-stimulating hormone peptide can facilitate paclitaxel nanoparticles to target ovarian carcinoma in vivo. Cancer Res. 2009, 69:6506-6514.
130. Imai A., Ohno T., Ohsuye K., Tamaya T. Expression of gonadotropin-releasing hormone receptor in human epithelial ovarian carcinoma. Ann. Clin. Biochem. 1994, 31(Pt 6):550-555.
131. So W.K., Cheng J.C., Poon S.L., Leung P.C.K. Gonadotropin-releasing hormone and ovarian cancer: a functional and mechanistic overview. FEBS J. 2008, 275:5496-5511.